Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin cream dose-ranging study in port-wine stains after pulsed dye laser therapy
2021-003604-40Phase 2Active
- Sponsor
- AFT Pharmaceuticals
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus in port-wine stain (3 arms), sponsored by AFT Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started Jan 2023; status: active.
02
Drugs
sirolimus
03
Conditions
port-wine stain
Beyond the preview
Go deeper on 2021-003604-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003604-40.